Literature DB >> 3865778

Pharmacokinetics of pefloxacin in renal insufficiency.

G Montay, C Jacquot, J Bariety, R Cunci.   

Abstract

The kinetics of pefloxacin has been studied after a single intravenous infusion of 8 mg X kg-1 in 15 male patients with various degrees of renal failure. No difference in distribution or elimination of the drug was observed between patients with mild or severe renal impairment. The mean volume of distribution (Vd area) and the mean plasma clearance were 2.03 l X kg-1 and 121.3 ml X min-1, respectively. The mean apparent elimination half-life was 13.5 h. These values are close to those observed in healthy subjects. No accumulation of the active N-desmethylmetabolite was observed in cases of severe failure as compared to mild impairment; its apparent elimination half-life was about twice that of the parent drug. The efficacy of a 4 haemodialysis in 6 additional anuric subjects done to remove pefloxacin from the body was poor.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3865778     DOI: 10.1007/bf00544092

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Improved high-performance liquid chromatographic determination of pefloxacin and its metabolite norfloxacin in human plasma and tissue.

Authors:  G Montay; J P Tassel
Journal:  J Chromatogr       Date:  1985-04-12

2.  A program package for simulation and parameter estimation in pharmacokinetic systems.

Authors:  D Z D'Argenio; A Schumitzky
Journal:  Comput Programs Biomed       Date:  1979-03

3.  High-performance liquid chromatography of pefloxacin and its main active metabolites in biological fluids.

Authors:  G Montay; Y Blain; F Roquet; A Le Hir
Journal:  J Chromatogr       Date:  1983-02-11

4.  [Comparison of the antimicrobial activity of pefloxacin (1589 RB), nalidixic acid and flumequin (author's transl)].

Authors:  A Thabaut; J L Durosoir
Journal:  Pathol Biol (Paris)       Date:  1982-06

5.  [Structure-activity relationships in the quinolone group: antibacterial activity of two new compounds (author's transl)].

Authors:  M Thibault; B Koumaré; C J Soussy; J Duval
Journal:  Ann Microbiol (Paris)       Date:  1981 May-Jun

6.  Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy.

Authors:  J A Hoogkamp-Korstanje
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

7.  Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.

Authors:  G Montay; Y Goueffon; F Roquet
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

8.  In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives.

Authors:  D L Van Caekenberghe; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

9.  Penetration of pefloxacin into cerebrospinal fluid of patients with meningitis.

Authors:  M Wolff; B Regnier; C Daldoss; M Nkam; F Vachon
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

  9 in total
  15 in total

1.  Pharmacokinetics of single-dose intravenous, oral, and intraperitoneal pefloxacin in patients on chronic ambulatory peritoneal dialysis.

Authors:  J L Schmit; L Hary; P Bou; H Renaud; P F Westeel; M Andrejak; A Fournier
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

2.  Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.

Authors:  Julien Brillault; Whocely Victor De Castro; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2009-10-12       Impact factor: 5.191

3.  Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.

Authors:  E Singlas; A Leroy; E Sultan; M Godin; B Moulin; A M Taburet; M Dhib; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

4.  Penetration of pefloxacin and its desmethyl metabolite into the uroepithelium after a 800-mg single oral dose in human patients.

Authors:  J L Moreau; M J Royer-Morrot; A Lozniewski; G Trackoen; P Delavault; R J Royer
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 5.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

6.  Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients.

Authors:  E Sultan; C Richard; M Pezzano; P Auzepy; E Singlas
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 7.  Pharmacokinetics of ciprofloxacin.

Authors:  T Bergan; A Dalhoff; R Rohwedder
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 8.  Clinical pharmacokinetics of the newer antibacterial 4-quinolones.

Authors:  M Neuman
Journal:  Clin Pharmacokinet       Date:  1988-02       Impact factor: 6.447

9.  Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients.

Authors:  R Bruno; M C Iliadis; B Lacarelle; V Cosson; J W Mandema; Y Le Roux; G Montay; A Durand; M Ballereau; M Alasia
Journal:  J Pharmacokinet Biopharm       Date:  1992-12

10.  Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline.

Authors:  W J Wijnands; T B Vree; A M Baars; C L van Herwaarden
Journal:  Drugs       Date:  1987       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.